BioSpace News Archive

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter operating and financial results.

Monopar Therapeutics Inc. today announced second quarter 2023 financial results and summarized recent developments.

Sol-Gel today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Tango Therapeutics, Inc. has agreed to sell approximately 15.5 million shares of its common stock in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private investment in public equity financing, at a per share price of $5.15.

Baird Medical Investment Holdings Limited today announced the 510(k) premarket notification submission of the Company’s Disposable Microwave Ablation (“MWA”) Needle and the Company’s MWA System to the U.S. Food and Drug Administration (FDA) for the treatment of soft tissue microwave ablation.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the second quarter ended June 30, 2023.

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT.

Bristol Myers Squibb announces induction into the Billion Dollar Roundtable, joining other Fortune 100 companies that have invested $1 billion with diverse-owned suppliers.

Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.